Company: CYTK
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013167
Chunk: 98

Company: CYTOKINETICS INC
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 98
---
 $89,167 |     |  $239,826 |     |  $219,978 |     | $548,970 |
| Mr. Smith      |     |         $37,564 |     |        $— |     |        $— |     |  $37,564 |
| Dr. Wierenga   |     |         $85,833 |     |  $239,826 |     |  $219,978 |     | $545,637 |
| Ms. Wysenski   |     |         $78,333 |     |  $239,826 |     |  $219,978 |     | $538,137 |

| (1) | Pursuant to the Equity in Lieu of Cash Retainer Option, the following non-employee directors received shares of our Common Stock in lieu of some or all their retainers pursuant to our Equity In Lieu of Cash Retainer Option program, as follows: Dr. Harrington – 784; Dr. Henderson – 1,334; Dr. Kaye – 784; Mr. Smith – 319; Dr. Wierenga – 391; and Ms. Wysenski – 391. Amounts in this column reflect an overpayment to Ms. Parshall in the amount of $5,000, Dr. Kaye in the amount of $1,250, Dr. Henderson in the amount of $1,250, Dr. Wierenga in the amount of $1,250, and Ms. Wysenski in the amount of $1,250, in each for payments of retainer fees, which will be offset against future retainer payments in 2025. |

| (2) | Automatic grants of stock options to non-employee directors were granted at the time of the 2024 annual meeting of stockholders (May 15, 2024) at an exercise price of $60.50 per share, which represents the fair market value of our Common Stock on the date of the grant. The amounts in the table reflect the grant-date fair value of stock option grants calculated in accordance with Topic 718. Assumptions used for the valuation of these grants are set forth in Note 8 of our audited consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. The amounts in this column also reflect the incremental fair value in connection with the modification described under “—Initial and